Literature DB >> 29461521

Rounding up lutetium.

Lars Öhrström1.   

Abstract

Entities:  

Year:  2018        PMID： 29461521     DOI： 10.1038/nchem.2938

Source DB:  PubMed          Journal:  Nat Chem        ISSN： 1755-4330            Impact factor:   24.427


× No keyword cloud information.
  5 in total

1.  3D solution structure of [Tyr3]octreotate derivatives in DMSO: structure differentiation of peptide core due to chelate group attachment and biologically active conformation.

Authors:  G A Spyroulias; A S Galanis; Ch Petrou; D Vahliotis; P Sotiriou; A Nikolopoulou; B Nock; T Maina; P Cordopatis
Journal:  Med Chem       Date:  2005-09       Impact factor: 2.745

2.  Crystal structures of two complexes of the rare-earth-DOTA-binding antibody 2D12.5: ligand generality from a chiral system.

Authors:  Todd M Corneillie; Andrew J Fisher; Claude F Meares
Journal:  J Am Chem Soc       Date:  2003-12-10       Impact factor: 15.419

3.  [177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney.

Authors:  Christina Swärd; Peter Bernhardt; Håkan Ahlman; Bo Wängberg; Eva Forssell-Aronsson; Maria Larsson; Johanna Svensson; Rauni Rossi-Norrlund; Lars Kölby
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

4.  Hedgehog inhibitor sonidegib potentiates 177Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice.

Authors:  Johan Spetz; Britta Langen; Nils Rudqvist; Toshima Z Parris; Khalil Helou; Ola Nilsson; Eva Forssell-Aronsson
Journal:  BMC Cancer       Date:  2017-08-08       Impact factor: 4.430

Review 5.  Photosensitizers in prostate cancer therapy.

Authors:  Taher Gheewala; Troy Skwor; Gnanasekar Munirathinam
Journal:  Oncotarget       Date:  2017-05-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.